```html

Uveitis Secondary to Sarcoidosis

Overview

Uveitis is inflammation of the uveal tract – the middle layer of the eye that includes the iris, ciliary body, and choroid. When the inflammation is triggered by systemic sarcoidosis, it is termed uveitis secondary to sarcoidosis. Sarcoidosis is a multisystem granulomatous disease of unknown cause that most often affects the lungs and lymph nodes, but it can involve virtually any organ, including the eyes.

Who it affects

• Adults aged 20‑40 years are most commonly diagnosed, although sarcoidosis can occur at any age.
• Women are slightly more likely than men to develop ocular sarcoidosis (≈55 % vs. 45 %).
• African‑American and Scandinavian populations have higher incidence rates (up to 3‑5 times higher than Caucasians in the United States).

Prevalence

• Overall sarcoidosis prevalence in the United States is about 10–35 cases per 100,000 people.<sup>CDC</sup>
• Ocular involvement occurs in 20‑30 % of patients with systemic sarcoidosis.<sup>Mayo Clinic</sup>
• Uveitis is the most common ocular manifestation, present in roughly 70‑80 % of sarcoid eye disease cases.<sup>NIH</sup>

Symptoms

Symptoms can be subtle at first and may affect one eye (unilateral) or both (bilateral). The following list includes the most frequently reported complaints:

• Redness – diffuse or sectoral injection of the conjunctiva.
• Eye pain – typically dull, deep, and worsens with eye movement.
• Photophobia – sensitivity to light, especially in bright environments.
• Blurred or decreased vision – may be intermittent or progressive.
• Floating spots (floaters) – due to inflammatory cells in the vitreous.
• Halos around lights – often a sign of corneal edema secondary to inflammation.
• Dry eye sensation – secondary to disrupted tear film.
• Eye discharge – usually watery rather than purulent.
• Swelling of the eyelids (blepharitis) – occasional in active disease.

Because sarcoidosis is systemic, many patients also notice other organ‑specific signs at the same time, such as persistent cough, shortness of breath, skin lesions, or joint pain.

Causes and Risk Factors

Underlying Mechanism

Sarcoidosis is characterized by non‑caseating granulomas—clusters of immune cells that form in response to an unidentified antigen. In the eye, these granulomas can involve the uveal tissue, retinal vessels, optic nerve, or lacrimal gland, leading to inflammation (uveitis). The exact trigger remains unknown, but genetic predisposition (e.g., HLA‑DRB1*03) and environmental exposures (organic dust, inorganic particles) are thought to play a role.<sup>NIH</sup>

Risk Factors

• Ethnicity – Higher rates in African‑American, Afro‑Caribbean, and Scandinavian descent.
• Age – Peak incidence between 20‑40 years.
• Female sex – Slightly increased risk of ocular involvement.
• Family history of sarcoidosis – Suggests a genetic component.
• Occupational exposure – Jobs involving wood dust, silica, or metal fumes have been linked to sarcoidosis.
• Immune dysregulation – Autoimmune diseases (e.g., rheumatoid arthritis) may coexist.

Diagnosis

Diagnosing uveitis secondary to sarcoidosis requires a combination of clinical eye examination, systemic work‑up, and sometimes tissue biopsy.

Ophthalmic Evaluation

• Slit‑lamp examination – Reveals anterior chamber cells/flare, keratic precipitates, or granulomatous lesions on the iris.
• Funduscopy (indirect ophthalmoscopy) – Detects vitreous haze, retinal vasculitis, choroidal granulomas, or optic disc edema.
• Optical coherence tomography (OCT) – Provides cross‑sectional images of the retina and choroid; useful for detecting macular edema.
• Fluorescein angiography (FA) or Indocyanine Green Angiography (ICGA) – Highlights retinal and choroidal vascular leakage.

Systemic Work‑up

• Chest radiograph or high‑resolution CT – Looks for hilar lymphadenopathy, a classic sarcoid sign.
• Serum angiotensin‑converting enzyme (ACE) level – Elevated in ~60 % of active sarcoidosis (not specific).
• Serum lysozyme – May be increased.
• Bronchoscopy with transbronchial lung biopsy – Provides tissue confirmation of non‑caseating granulomas.
• Skin biopsy – If cutaneous lesions are present.
• Laboratory exclusion – Tests for infectious uveitis (e.g., syphilis, tuberculosis, toxoplasmosis) are essential to rule out mimickers.

Diagnostic Criteria

According to the International Workshop on Ocular Sarcoidosis (IWOS), a “probable” diagnosis can be made when ocular findings are compatible and at least two systemic investigations support sarcoidosis, whereas “definite” diagnosis requires histopathologic confirmation.<sup>Cleveland Clinic</sup>

Treatment Options

Treatment aims to control inflammation, preserve vision, and manage systemic disease. Therapy is usually coordinated between ophthalmologists, pulmonologists/rheumatologists, and primary care providers.

First‑Line Anti‑Inflammatory Therapy

• Topical corticosteroid drops (e.g., prednisolone acetate 1 %): for mild anterior uveitis.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – oral ibuprofen or naproxen may help with peripheral inflammation.

Systemic Corticosteroids

Prednisone 0.5–1 mg/kg/day is the mainstay for moderate‑to‑severe ocular sarcoidosis. A typical taper lasts 3–6 months, guided by ocular response and side‑effect profile.

Steroid‑Sparing Immunomodulatory Agents

Because long‑term steroids cause cataracts, glaucoma, osteoporosis, and metabolic complications, many patients require steroid‑sparing drugs:

• Methotrexate – 10–25 mg weekly; monitor liver function and blood counts.
• Mycophenolate mofetil – 1–1.5 g twice daily; useful for chronic posterior uveitis.
• Azathioprine – 2–3 mg/kg/day; TPMT activity testing before initiation.
• Cyclosporine A – 2–5 mg/kg/day; watch renal function and blood pressure.

Biologic Therapies

In refractory cases, tumor necrosis factor‑α (TNF‑α) inhibitors have shown high efficacy:

• Adalimumab – FDA‑approved for non‑infectious uveitis; loading dose 80 mg then 40 mg every 2 weeks.
• Infliximab – Intravenous infusion (5 mg/kg at weeks 0, 2, 6, then every 8 weeks).

Biologics require screening for latent TB and hepatitis before starting.

Local Steroid Delivery (when systemic therapy is contraindicated)

• Periocular (sub‑tenon) triamcinolone injection – Provides high intra‑ocular levels for 3–4 months.
• Intravitreal dexamethasone implant (Ozurdex) – Useful for chronic posterior segment inflammation.

Lifestyle & Supportive Measures

• Protect eyes from bright light with sunglasses (UV‑blocking).
• Use preservative‑free artificial tears for dry‑eye symptoms.
• Maintain good control of systemic sarcoidosis (e.g., smoking cessation, pulmonary rehab).
• Regular eye‑pressure checks to detect steroid‑induced glaucoma early.

Living with Uveitis Secondary to Sarcoidosis

Daily Management Tips

• Medication adherence – Use a pill organizer or smartphone reminders; never stop steroids abruptly.
• Follow‑up schedule – Typically every 4–6 weeks during active disease, then every 3–6 months once stable.
• Self‑monitoring – Keep a symptom diary (pain, vision changes, photophobia). Report any worsening promptly.
• Protective eyewear – Wear wrap‑around sunglasses outdoors and safety glasses during activities that could cause eye injury.
• Healthy diet – Anti‑inflammatory foods (omega‑3 fatty acids, fruits, vegetables) may support overall disease control.
• Exercise – Regular moderate exercise improves pulmonary function and reduces systemic inflammation, but avoid activities that increase intra‑ocular pressure (e.g., heavy weight lifting) during active inflammation.

Psychosocial Support

Living with a chronic eye disease can be stressful. Consider:

• Joining sarcoidosis or uveitis support groups (online or in‑person).
• Counselling or therapy for anxiety/depression, which are more common in patients with visual impairment.
• Vision‑rehabilitation services if vision loss persists.

Prevention

Because sarcoidosis cannot be prevented outright, the focus is on early detection and reducing flare‑ups:

• Regular medical screening – Annual eye exams for anyone diagnosed with sarcoidosis, even if asymptomatic.
• Prompt treatment of systemic disease – Effective control of lung or skin involvement lessens the likelihood of ocular spread.
• Avoid known triggers – Limit exposure to occupational dusts, silica, and other inhaled particulates.
• Vaccinations – Keep up to date (influenza, COVID‑19, pneumococcal) to reduce infections that could exacerbate inflammation.

Complications

If inflammation is not adequately controlled, several vision‑threatening complications can develop:

• Cataract formation – Accelerated by chronic steroid use and inflammation.
• Glaucoma – Steroid‑induced or secondary to trabecular meshwork damage.
• Macular edema – Fluid accumulation in the central retina, leading to central vision loss.
• Epiretinal membrane & vitreoretinal traction – Can cause distortion of vision.
• Choroidal neovascularization – Abnormal blood vessels beneath the retina, often requiring anti‑VEGF injections.
• Optic neuropathy – Permanent visual field defects if optic nerve becomes inflamed.
• Permanent visual acuity loss – Reported in up to 10 % of patients with untreated posterior uveitis.<sup>NIH</sup>

When to Seek Emergency Care

References

1. Mayo Clinic. Sarcoidosis. https://www.mayoclinic.org/diseases-conditions/sarcoidosis/symptoms-causes/syc-20350303 (accessed June 2026).
2. CDC. Multisystem Granulomatous Disease (Sarcoidosis) FastStats. https://www.cdc.gov/nchs/fastats/multisystem-granulomatous-disease.htm (accessed June 2026).
3. NIH National Institute of Allergy and Infectious Diseases. Uveitis in Sarcoidosis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987315/ (accessed June 2026).
4. Cleveland Clinic. International Workshop on Ocular Sarcoidosis (IWOS) Criteria. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852351/ (accessed June 2026).
5. World Health Organization. Guidelines for the Management of Uveitis. 2022.
6. American Academy of Ophthalmology. Uveitis Preferred Practice Pattern. https://www.aao.org/preferred-practice-pattern/uveitis-ppp (accessed June 2026).

```